Key result
De novo solid malignancies develop in ~3% of heart transplant recipients, predominantly affecting men.
Why the study?
The incidence and clinical spectrum of de novo solid tumors in a uniform population of heart transplant recipients remains uncertain.
Population
712 patients who underwent cardiac transplantation
Design
Retrospective cohort study with clinical chart review and telephone interviews
Authors
Loading...
May support closer post-transplant malignancy surveillance in males; leaves open whether intensified pretransplant screening alters outcomes.
Cohort (n=712)
De novo solid malignancies occur in approximately 3.3% of heart transplant recipients, predominantly in males with a smoking history, highlighting the need for aggressive pretransplantation screening for occult malignancy.
Goldstein et al. (1995) conducted a cohort in Cardiac transplantation (n=712). Cardiac transplantation was evaluated on De novo solid malignancies. De novo solid malignancies occurred in 3.3% of cardiac transplant recipients (21 of 633 patients at risk), with a striking male predominance and a mean interval to diagnosis of 35 months.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: